<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRUSOPT- dorzolamide hydrochloride solution </strong><br>Merck Sharp &amp; Dohme Corp.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TRUSOPT safely and effectively. See full prescribing information for TRUSOPT.<br><br>TRUSOPT<span class="Sup">®</span> (dorzolamide hydrochloride ophthalmic solution) 2%<br>Initial U.S. Approval: 1994</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">TRUSOPT is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> or open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The dose is one drop of TRUSOPT in the affected eye(s) three times daily. TRUSOPT may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. (<a href="#S2">2</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Solution containing 20 mg/mL dorzolamide. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">TRUSOPT is contraindicated in patients who are hypersensitive to any component of this product. (<a href="#S4">4</a>, <a href="#S5.1">5.1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Sulfonamide <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#S5.1">5.1</a>)</li>
<li>Bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> (<a href="#S5.2">5.2</a>)</li>
<li>Corneal Endothelium (<a href="#S5.3">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> (<a href="#S5.4">5.4</a>)</li>
<li>Acute Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> (<a href="#S5.5">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">The most frequently reported adverse reactions associated with TRUSOPT were ocular burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> immediately following ocular administration (approximately one-third of patients). Approximately one-quarter of patients noted a bitter taste following administration. <span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">Superficial punctate keratitis</span> occurred in 10 to 15% of patients and signs and symptoms of ocular <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> in approximately 10%. (<a href="#S6">6</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Potential additive effect of oral carbonic anhydrase inhibitor with TRUSOPT. (<a href="#S7.1">7.1</a>)</li>
<li>Potential acid-base and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>. (<a href="#S7.2">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Sulfonamide <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Corneal Endothelium</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Acute Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Oral Carbonic Anhydrase Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	High-Dose Salicylate Therapy</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1	Sulfonamide Reactions</a></h2>
<h2><a href="#section-15.2" class="toc">17.2	Intercurrent Ocular Conditions</a></h2>
<h2><a href="#section-15.3" class="toc">17.3	Handling Ophthalmic Solutions</a></h2>
<h2><a href="#section-15.4" class="toc">17.4	Concomitant Topical Ocular Therapy</a></h2>
<h2><a href="#section-15.5" class="toc">17.5	Contact Lens Use</a></h2>
<h2><a href="#section-15.6" class="toc">17.6	Patient Instructions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">TRUSOPT<span class="Sup">®</span> Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> or open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dose is one drop of TRUSOPT Ophthalmic Solution in the affected eye(s) three times daily.</p>
<p>TRUSOPT may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Solution containing 20 mg/mL dorzolamide (22.3 mg of dorzolamide hydrochloride).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">TRUSOPT is contraindicated in patients who are hypersensitive to any component of this product <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Sulfonamide <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">TRUSOPT contains dorzolamide, a sulfonamide; and although administered topically, it is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of TRUSOPT. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occur, discontinue the use of this preparation <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S17.3">Patient Counseling Information (17.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></h2>
<p class="First">There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Corneal Endothelium</h2>
<p class="First">Carbonic anhydrase activity has been observed in both the cytoplasm and around the plasma membranes of the corneal endothelium. There is an increased potential for developing <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span> in patients with low endothelial cell counts. Caution should be used when prescribing TRUSOPT to this group of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">In clinical studies, local ocular adverse effects, primarily <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and lid reactions, were reported with chronic administration of TRUSOPT. Many of these reactions had the clinical appearance and course of an allergic-type reaction that resolved upon discontinuation of drug therapy. If such reactions are observed, TRUSOPT should be discontinued and the patient evaluated before considering restarting the drug <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Acute Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">The management of patients with acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> requires therapeutic interventions in addition to ocular hypotensive agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics">Controlled clinical trials:</span> The most frequent adverse reactions associated with TRUSOPT were ocular burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> immediately following ocular administration (approximately one-third of patients). Approximately one-quarter of patients noted a bitter taste following administration. <span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">Superficial punctate keratitis</span> occurred in 10 to 15% of patients and signs and symptoms of ocular <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> in approximately 10%. Reactions occurring in approximately 1 to 5% of patients were <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and lid reactions <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">eye redness</span>, tearing, dryness, and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>. Other ocular reactions and systemic reactions were reported infrequently, including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; and, rarely, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="79873" conceptname="Urolith">urolithiasis</span>, and <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span>.</p>
<p>In a 3-month, double-masked, active-treatment-controlled, multicenter study in pediatric patients, the adverse reactions profile of TRUSOPT was comparable to that seen in adult patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of TRUSOPT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>; <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>, transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span>, <span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">choroidal detachment</span> following filtration surgery, eyelid crusting; <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>; <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Oral Carbonic Anhydrase Inhibitors</h2>
<p class="First">There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and TRUSOPT. The concomitant administration of TRUSOPT and oral carbonic anhydrase inhibitors is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	High-Dose Salicylate Therapy</h2>
<p class="First">Although acid-base and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving TRUSOPT.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Teratogenic Effects.</span> Pregnancy Category C. Developmental toxicity studies with dorzolamide hydrochloride in rabbits at oral doses of ≥ 2.5 mg/kg/day revealed malformations of the vertebral bodies. These malformations occurred at doses that caused <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> with decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in dams and decreased fetal weights. No treatment-related malformations were seen at 1 mg/kg/day. These doses represent estimated plasma C<span class="Sub">max</span> levels in rabbits, 37 and 15 times higher than the lower limit of detection in human plasma following ocular administration, respectively.</p>
<p>There are no adequate and well-controlled studies in pregnant women. TRUSOPT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">In a study of dorzolamide hydrochloride in lactating rats, decreases in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of 5 to 7% in offspring at an oral dose of 7.5 mg/kg/day were seen during lactation. A slight delay in postnatal development (incisor <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>, vaginal canalization and eye openings), secondary to lower fetal body weight, was noted. This dose represents an estimated plasma C<span class="Sub">max</span> level in rats, 52 times higher than the lower limit of detection in human plasma following ocular administration.</p>
<p>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from TRUSOPT, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of TRUSOPT have been demonstrated in pediatric patients in a 3-month, multicenter, double-masked, active-treatment-controlled trial.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Dorzolamide has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl &lt; 30 mL/min). Because dorzolamide and its metabolite are excreted predominantly by the kidney, TRUSOPT is not recommended in such patients.</p>
<p>Dorzolamide has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and should therefore be used with caution in such patients<span class="Italics">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span>, development of an acidotic state, and possible central nervous system effects may occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">TRUSOPT<span class="Sup">®</span> (dorzolamide hydrochloride ophthalmic solution) is a carbonic anhydrase inhibitor formulated for topical ophthalmic use.</p>
<p>Dorzolamide hydrochloride is described chemically as: (4<span class="Italics">S-trans</span>)-4-(ethylamino)-5,6-dihydro-6-methyl-4<span class="Italics">H</span>-thieno[2,3-<span class="Italics">b</span>]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride. Dorzolamide hydrochloride is optically active. The specific rotation is</p>
<table class="Noautorules" width="35%">
<col align="center" valign="top" width="30%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr>
<td align="center">α</td>
<td align="left">25°</td>
<td align="left">(C=1, water) = ~ -17°.</td>
</tr>
<tr>
<td align="center"></td>
<td align="left">405</td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p>Its empirical formula is C<span class="Sub">10</span>H<span class="Sub">16</span>N<span class="Sub">2</span>O<span class="Sub">4</span>S<span class="Sub">3</span>∙HCl and its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26d26f80-aebf-441c-6383-327cb95eae4d&amp;name=trusopt-01.jpg"></div>
<p>Dorzolamide hydrochloride has a molecular weight of 360.9 and a melting point of about 264°C. It is a white to off-white, crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol.</p>
<p>TRUSOPT Sterile Ophthalmic Solution is supplied as a sterile, isotonic, buffered, slightly viscous, aqueous solution of dorzolamide hydrochloride. The pH of the solution is approximately 5.6, and the osmolarity is 260-330 mOsM. Each mL of TRUSOPT 2% contains 20 mg dorzolamide (22.3 mg of dorzolamide hydrochloride). Inactive ingredients are hydroxyethyl cellulose, mannitol, sodium citrate dihydrate, sodium hydroxide (to adjust pH) and water for injection. Benzalkonium chloride 0.0075% is added as a preservative.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and the <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP).</p>
<p>TRUSOPT Ophthalmic Solution contains dorzolamide hydrochloride, an inhibitor of human carbonic anhydrase II. Following topical ocular administration, TRUSOPT reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> and glaucomatous visual field loss.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, drug and metabolite concentrations in RBCs and plasma and carbonic anhydrase inhibition in RBCs were measured.</p>
<p>Dorzolamide accumulates in RBCs during chronic dosing as a result of binding to CA-II. The parent drug forms a single N-desethyl metabolite, which inhibits CA-II less potently than the parent drug but also inhibits CA-I. The metabolite also accumulates in RBCs where it binds primarily to CA-I. Plasma concentrations of dorzolamide and metabolite are generally below the assay limit of quantitation (15nM). Dorzolamide binds moderately to plasma proteins (approximately 33%).</p>
<p>Dorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine. After dosing is stopped, dorzolamide washes out of RBCs nonlinearly, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about four months.</p>
<p>To simulate the systemic exposure after long-term topical ocular administration, dorzolamide was given orally to eight healthy subjects for up to 20 weeks. The oral dose of 2 mg twice daily closely approximates the amount of drug delivered by topical ocular administration of dorzolamide 2% three times daily. Steady state was reached within 8 weeks. The inhibition of CA-II and total carbonic anhydrase activities was below the degree of inhibition anticipated to be necessary for a pharmacological effect on renal function and respiration in healthy individuals.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a two-year study of dorzolamide hydrochloride administered orally to male and female Sprague-Dawley rats, urinary bladder <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> were seen in male rats in the highest dosage group of 20 mg/kg/day. <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">Papillomas</span> were not seen in rats given oral doses of 1 mg/kg/day. These doses represent estimated plasma C<span class="Sub">max</span> levels in rats, 138 and 7 times higher than the lower limit of detection in human plasma following ocular administration, respectively.</p>
<p>No treatment-related tumors were seen in a 21-month study in female and male mice given oral doses up to 75 mg/kg/day. This dose represents an estimated plasma C<span class="Sub">max</span> level in mice, 582 times higher than the lower limit of detection in human plasma following ocular administration.</p>
<p>The increased incidence of urinary bladder <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> seen in the high-dose male rats is a class-effect of carbonic anhydrase inhibitors in rats. Rats are particularly prone to developing <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> in response to foreign bodies, compounds causing <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>, and diverse sodium salts.</p>
<p>No changes in bladder urothelium were seen in dogs given oral dorzolamide hydrochloride for one year at 2 mg/kg/day or monkeys dosed topically to the eye for one year. An oral dose of 2 mg/kg/day in dogs represents an estimated plasma C<span class="Sub">max</span> level, 137 times higher than the lower limit of detection in human plasma following ocular administration. The topical ophthalmic dose in monkeys was approximately equivalent to the human topical ophthalmic dose.</p>
<p>The following tests for mutagenic potential were negative: (1) <span class="Italics">in vivo</span> (mouse) cytogenetic assay; (2) <span class="Italics">in vitro</span> chromosomal aberration assay; (3) alkaline elution assay; (4) V-79 assay; and (5) Ames test.</p>
<p>In reproduction studies of dorzolamide hydrochloride in rats, there were no adverse effects on the reproductive capacity of males or females at doses of 15 and 7.5 mg/kg/day, respectively. These doses represent estimated plasma C<span class="Sub">max</span> levels in rats, 104 and 52 times higher than the lower limit of detection in human plasma following ocular administration, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of TRUSOPT was demonstrated in clinical studies in the treatment of elevated intraocular pressure in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> (baseline IOP ≥ 23 mmHg). The IOP-lowering effect of TRUSOPT was approximately 3 to 5 mmHg throughout the day and this was consistent in clinical studies of up to one year duration.</p>
<p>The efficacy of TRUSOPT when dosed less frequently than three times a day (alone or in combination with other products) has not been established.</p>
<p>In a one year clinical study, the effect of TRUSOPT 2% three times daily on the corneal endothelium was compared to that of betaxolol ophthalmic solution twice daily and timolol maleate ophthalmic solution 0.5% twice daily. There were no statistically significant differences between groups in corneal endothelial cell counts or in corneal thickness measurements. There was a mean loss of approximately 4% in the endothelial cell counts for each group over the one year period.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">TRUSOPT is supplied in an OCUMETER<span class="Sup">®</span> PLUS container, a white, translucent, HDPE plastic ophthalmic dispenser with a controlled drop tip and a white polystyrene cap with orange label as follows:</p>
<p><span class="Bold">NDC</span> 0006-3519-36, 10 mL, in an 18 mL capacity bottle.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Italics">Storage</span></p>
<p>Store TRUSOPT Ophthalmic Solution at 15-30°C (59-86°F). Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (<a href="#ifu">Instructions for Use</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1	Sulfonamide Reactions</h2>
<p class="First">TRUSOPT is a sulfonamide and although administered topically is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration. Advise patients that if serious or unusual reactions including severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> or signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occur, they should discontinue the use of the product <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2	Intercurrent Ocular Conditions</h2>
<p class="First">Advise patients that if they have ocular surgery or develop an intercurrent ocular condition (e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>), they should immediately seek their physician's advice concerning the continued use of the present multidose container.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3	Handling Ophthalmic Solutions</h2>
<p class="First">Instruct patients that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4	Concomitant Topical Ocular Therapy</h2>
<p class="First">If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5	Contact Lens Use</h2>
<p class="First">Advise patients that TRUSOPT contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following TRUSOPT administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6	Patient Instructions</h2>
<p class="First">Advise patients that if they develop any ocular reactions, particularly <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and lid reactions, they should discontinue use and seek their physician's advice.</p>
<p>Instruct patients to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manuf. for: Merck Sharp &amp; Dohme Corp., a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>By: Laboratoires Merck Sharp &amp; Dohme-Chibret<br>Clermont Ferrand Cedex 9, 63963, France</p>
<p>Copyright © 1994, 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>Revised: 02/2014</p>
<p>uspi-mk0507-os-1402r013</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ifu"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">INSTRUCTIONS FOR USE</span><br>TRUSOPT<span class="Sup">®</span> ("<span class="Bold">TRU-sopt</span>")<br>(dorzolamide hydrochloride ophthalmic solution) 2%</p>
<p><span class="Bold">Before using your TRUSOPT</span></p>
<p>Before using your TRUSOPT for the first time, make sure the safety strip on the front of the bottle is unbroken. A gap between the bottle and the cap is normal for an unopened bottle. (See <a href="#figa">Figure A</a>).</p>
<div class="Figure">
<a name="figa"></a><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26d26f80-aebf-441c-6383-327cb95eae4d&amp;name=trusopt-02.jpg"><p class="MultiMediaCaption">Figure A</p>
</div>
<p><span class="Bold">Step 1.</span> Wash your hands.</p>
<p><span class="Bold">Step 2.</span> Tear off the safety strip to break the seal. See <a href="#figb">Figure B</a>.</p>
<div class="Figure">
<a name="figb"></a><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26d26f80-aebf-441c-6383-327cb95eae4d&amp;name=trusopt-03.jpg"><p class="MultiMediaCaption">Figure B</p>
</div>
<p><span class="Bold">Step 3.</span> Unscrew the cap by turning in the direction of the arrows on the top of the cap. <span class="Bold">Do not</span> pull the cap directly up and away from the bottle. Pulling the cap directly up will keep your TRUSOPT dispenser from working the right way. See <a href="#figc">Figure C</a>.</p>
<div class="Figure">
<a name="figc"></a><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26d26f80-aebf-441c-6383-327cb95eae4d&amp;name=trusopt-04.jpg"><p class="MultiMediaCaption">Figure C</p>
</div>
<p><span class="Bold">Giving your TRUSOPT drops</span></p>
<p><span class="Bold">Step 4.</span> Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and your eye. See <a href="#figd">Figure D</a>.</p>
<div class="Figure">
<a name="figd"></a><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26d26f80-aebf-441c-6383-327cb95eae4d&amp;name=trusopt-05.jpg"><p class="MultiMediaCaption">Figure D</p>
</div>
<p><span class="Bold">Step 5.</span> Turn your TRUSOPT dispenser upside down and press lightly with your thumb or index finger over the "Finger Push Area" until a single drop is placed in your eye. <span class="Bold">Do not</span> touch your eye or eyelid with the dropper tip. See <a href="#fige">Figure E</a>.</p>
<div class="Figure">
<a name="fige"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26d26f80-aebf-441c-6383-327cb95eae4d&amp;name=trusopt-06.jpg"><p class="MultiMediaCaption">Figure E</p>
</div>
<p><span class="Bold">Step 6.</span> If the medicine does not drop easily from the TRUSOPT dispenser after you open it for the first time, replace the cap on the bottle and tighten. <span class="Bold">Do not</span> over tighten. Remove the cap by turning the cap in the direction of the arrows on the top of the cap. See <a href="#figf">Figure F</a>. This should make the hole on the dispenser tip larger. <span class="Bold">Do not</span> try to make the hole of the dispenser tip larger in any other way. The dispenser tip is made to provide a single drop. Repeat Steps 4 and 5 to give your TRUSOPT drop.</p>
<div class="Figure">
<a name="figf"></a><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26d26f80-aebf-441c-6383-327cb95eae4d&amp;name=trusopt-07.jpg"><p class="MultiMediaCaption">Figure F</p>
</div>
<p><span class="Bold">Step 7.</span> If your doctor has told you to use TRUSOPT drops in both eyes, repeat Steps 4 and 5.</p>
<p><span class="Bold">After using your TRUSOPT</span></p>
<p><span class="Bold">Step 8.</span> Replace the cap by turning it until it is firmly touching your TRUSOPT dispenser. The arrow on the left side of the cap must be lined up with the arrow on the left side of the TRUSOPT dispenser label for it to be closed correctly. <span class="Bold">Do not</span> over tighten or you may damage the TRUSOPT dispenser and cap. See <a href="#figg">Figure G</a>.</p>
<div class="Figure">
<a name="figg"></a><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26d26f80-aebf-441c-6383-327cb95eae4d&amp;name=trusopt-08.jpg"><p class="MultiMediaCaption">Figure G</p>
</div>
<p>After you have used all of your TRUSOPT doses, there will be some TRUSOPT medicine left in the dispenser. <span class="Bold">Do not</span> try to remove the extra medicine from the TRUSOPT dispenser. Throw away your TRUSOPT dispenser in your household trash.</p>
<p><span class="Bold">How should I store TRUSOPT?</span></p>
<ul class="Disc">
<li>Store TRUSOPT between 59°F to 86°F (15°C to 30°C)</li>
<li>Protect from light</li>
<li>Safely throw away medicine that is out of date or no longer needed.</li>
</ul>
<p><span class="Bold">Keep TRUSOPT and all medicines out of the reach of children.</span></p>
<p><span class="Bold">Important information about using TRUSOPT</span></p>
<ul class="Disc">
<li>If you have any eye or <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, especially <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> or eyelid reactions to TRUSOPT, stop using it and call your doctor right away.</li>
<li>If you have eye surgery or have a problem such as <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of your eye while using TRUSOPT, call your doctor right away.</li>
<li>If you do not handle eye medicines the right way the medicine can become contaminated. If the tip of the dispenser touches your eye or areas around your eye, the tip can become contaminated with bacteria which can cause an <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infection</span> and other serious problems including loss of eyesight.</li>
<li>If you use other eye medicines dropped onto the eye like TRUSOPT, use the medicines at least 5 minutes before or after you use TRUSOPT.</li>
<li>TRUSOPT contains benzalkonium chloride which may be absorbed by soft contact lenses. If you wear contact lenses, remove them before you use your TRUSOPT. You can place your contact lenses back into your eyes 15 minutes after using your TRUSOPT.</li>
</ul>
<p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<p class="First">Manuf. for: Merck Sharp &amp; Dohme Corp., a subsidiary of <br><span class="Bold">MERCK &amp; CO., Inc.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>By: Laboratoires Merck Sharp &amp; Dohme-Chibret <br> Clermont Ferrand Cedex 9, 63963, France</p>
<p>Copyright © 2000, 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br> All rights reserved.</p>
<p>Revised: 02/2014</p>
<p>ifu-mk0507-os-1402r013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_4686318a-f0f0-47f6-89cb-821fc2614082"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mL Bottle Carton</h1>
<p class="First"><span class="Bold">NDC</span> 0006-3519-36</p>
<p><span class="Bold">10 mL<br>OCUMETER</span><span class="Sup">®</span><span class="Bold"> PLUS<br> OPHTHALMIC DISPENSER<br>STERILE<br> OPHTHALMIC SOLUTION</span></p>
<p><span class="Bold">TRUSOPT</span><span class="Sup">®</span><br><span class="Bold">(DORZOLAMIDE<br> HYDROCHLORIDE<br> OPHTHALMIC SOLUTION)</span></p>
<p><span class="Bold">2%</span><br>Dorzolamide Equivalent<br>(Dorzolamide Hydrochloride<br> 22.3 mg/mL)</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26d26f80-aebf-441c-6383-327cb95eae4d&amp;name=trusopt-09.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRUSOPT 		
					</strong><br><span class="contentTableReg">dorzolamide hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0006-3519</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DORZOLAMIDE HYDROCHLORIDE</strong> (DORZOLAMIDE) </td>
<td class="formItem">DORZOLAMIDE</td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0006-3519-36</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020408</td>
<td class="formItem">12/09/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Merck Sharp &amp; Dohme Corp.
							(001317601)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Laboratoires Merck Sharp &amp; Dohme-Chibret</td>
<td class="formItem"></td>
<td class="formItem">493743686</td>
<td class="formItem">MANUFACTURE(0006-3519), PACK(0006-3519)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Merck Sharp &amp; Dohme Corp.</td>
<td class="formItem"></td>
<td class="formItem">001705110</td>
<td class="formItem">API MANUFACTURE(0006-3519)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ZACH SYSTEM SPA</td>
<td class="formItem"></td>
<td class="formItem">517259979</td>
<td class="formItem">API MANUFACTURE(0006-3519)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0ab2a390-2925-4b2c-98d3-24f338eee2c2</div>
<div>Set id: 26d26f80-aebf-441c-6383-327cb95eae4d</div>
<div>Version: 9</div>
<div>Effective Time: 20140217</div>
</div>
</div> <div class="DistributorName">Merck Sharp &amp; Dohme Corp.</div></p>
</body></html>
